Claro Advisors LLC purchased a brand new place in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) throughout the third quarter, in accordance with its most up-to-date submitting with the SEC. The fund purchased 6,374 shares of the corporate’s inventory, valued at roughly $497,000.
Different hedge funds and different institutional traders additionally lately made adjustments to their positions within the firm. American Worldwide Group Inc. grew its place in shares of AstraZeneca by 2.0% throughout the 4th quarter. American Worldwide Group Inc. now owns 40,464 shares of the corporate’s inventory valued at $2,725,000 after buying a further 775 shares throughout the interval. Cooper Monetary Group raised its stake in shares of AstraZeneca by 15.0% within the first quarter. Cooper Monetary Group now owns 7,367 shares of the corporate’s inventory valued at $499,000 after shopping for a further 963 shares throughout the interval. Ballentine Companions LLC lifted its place in shares of AstraZeneca by 32.5% throughout the 1st quarter. Ballentine Companions LLC now owns 23,615 shares of the corporate’s inventory valued at $1,600,000 after shopping for a further 5,795 shares over the past quarter. AdvisorNet Monetary Inc grew its stake in shares of AstraZeneca by 10.7% throughout the 1st quarter. AdvisorNet Monetary Inc now owns 21,973 shares of the corporate’s inventory value $1,489,000 after buying a further 2,120 shares throughout the interval. Lastly, International Property Advisory LLC bought a brand new stake in AstraZeneca within the 1st quarter value about $2,734,000. 20.35% of the inventory is owned by hedge funds and different institutional traders.
AstraZeneca Buying and selling Up 0.3 %
Shares of AZN inventory opened at $78.26 on Friday. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week excessive of $87.68. The enterprise’s fifty day transferring common is $81.13 and its 200 day transferring common is $78.20. The corporate has a debt-to-equity ratio of 0.69, a fast ratio of 0.69 and a present ratio of 0.89. The corporate has a market capitalization of $242.65 billion, a PE ratio of 38.36, a price-to-earnings-growth ratio of 1.44 and a beta of 0.46.
AstraZeneca (NASDAQ:AZN – Get Free Report) final issued its quarterly earnings outcomes on Thursday, July twenty fifth. The corporate reported $0.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. The agency had income of $12.45 billion throughout the quarter, in comparison with the consensus estimate of $12.62 billion. AstraZeneca had a return on fairness of 29.34% and a web margin of 13.11%. The corporate’s income for the quarter was up 9.1% on a year-over-year foundation. Throughout the identical quarter final 12 months, the corporate posted $1.08 EPS. On common, equities analysis analysts anticipate that AstraZeneca PLC will submit 4.07 EPS for the present fiscal 12 months.
AstraZeneca Cuts Dividend
The enterprise additionally lately declared a Semi-Annual dividend, which was paid on Monday, September ninth. Stockholders of document on Friday, August ninth have been issued a $0.49 dividend. This represents a dividend yield of 1.8%. The ex-dividend date was Friday, August ninth. AstraZeneca’s payout ratio is 48.04%.
Analysts Set New Value Targets
Plenty of equities analysts have weighed in on AZN shares. Erste Group Financial institution upgraded shares of AstraZeneca from a “maintain” ranking to a “purchase” ranking in a analysis report on Wednesday, September eleventh. Citigroup upgraded shares of AstraZeneca to a “strong-buy” ranking in a analysis word on Monday, June twenty fourth. TD Cowen elevated their goal worth on AstraZeneca from $90.00 to $95.00 and gave the inventory a “purchase” ranking in a analysis report on Monday, August twelfth. Barclays upgraded AstraZeneca to a “strong-buy” ranking in a analysis report on Monday, June twenty fourth. Lastly, Deutsche Financial institution Aktiengesellschaft lower AstraZeneca from a “maintain” ranking to a “promote” ranking in a report on Friday, September thirteenth. One equities analysis analyst has rated the inventory with a promote ranking, one has issued a maintain ranking, seven have assigned a purchase ranking and two have assigned a powerful purchase ranking to the corporate’s inventory. Based on MarketBeat, AstraZeneca has a median ranking of “Reasonable Purchase” and a consensus goal worth of $89.75.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical firm, focuses on the invention, improvement, manufacture, and commercialization of prescription medicines. The corporate’s marketed merchandise embrace Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Tales
Wish to see what different hedge funds are holding AZN? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Obtain Information & Scores for AstraZeneca Day by day – Enter your electronic mail tackle under to obtain a concise every day abstract of the most recent information and analysts’ scores for AstraZeneca and associated corporations with MarketBeat.com’s FREE every day electronic mail publication.